Sun Pharmaceutical to acquire shares of Israeli firm Tarsius Pharma for USD 3 million

PTI | Published: 10th September 2018 05:44 PM
Sun Pharmaceutical Industries ( Photo| REUTERS)

NEW DELHI: Drug major Sun Pharmaceutical Industries Monday said it has agreed to acquire 18.75 per cent shares of Israel-based Tarsius Pharma for a cash consideration of USD 3 million (over Rs 21 crore).

One of the company's wholly-owned subsidiaries has agreed to acquire 3,45,622 ordinary shares of Tarsius Pharma, of nominal value of NIS 0.01 each by way of subscription, representing 18.75 per cent of shares of Tarsius on a fully diluted basis, Sun Pharma said in a filing to BSE.

ALSO READ | Sun Pharma gets USFDA nod for prostate cancer drug

"Cost of acquisition is USD 3 million," it added.

The indicative time period for completion of the acquisition is before September 15, 2018, Sun Pharma said.

Tarsius is an early stage research and development company focusing on development of drug candidates in the field of ophthalmology, it added.

Shares of Sun Pharmaceutical Industries closed at Rs 639.50 per scrip on BSE, down 3.72 per cent from its previous close.

Tags : Sun Pharmaceutical Industries Tarsius Pharma ophthalmology

More from this section

Michael Kors takes over fashion icon Versace in USD 2 billion deal
Yes Bank to seek RBI nod to extend CEO's term beyond January
Post-2014, India richer by 601 new billionaires, Mukesh Ambani on top: Barclays
Millenial women lead in online search for properties, men ahead in buying decisions: Study
Cabinet may consider converting GSTN to government entity Wednesday